证券代码：300253 证券简称：卫宁健康 公告编号：2024-038 卫宁健康科技集团股份有限公司 第六届监事会第三次会议决议公告 经审议，监事会认为：董事会编制和审核公司 2024 年第一季度 报告的程序符合法律、行政法规和中国证监会的规定，报告内容真实、 准确、完整地反映了公司的实际情况，不存在任何虚假记载、误导性 陈述或者重大遗漏。 《2024 年第一季度报告》详见中国证监会指定的创业板信息披 露网站。 特此公告。 本公司及监事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 卫宁健康科技集团股份有限公司（以下简称"公司"）于 2024 年 4 月 25 日在公司会议室以现场方式召开第六届监事会第三次会议。 会议通知于 2024 年 4 月 22 日以专人送达及电子邮件方式发出。会议 应出席监事 3 人，实际出席监事 3 人。会议由监事会主席李琳主持。 本次监事会的召集和召开符合《中华人民共和国公司法》和《公司章 程》的规定。经全体监事表决，形成决议如下： 会议以 3 票同意、0 票反对、0 票弃权的结果审议通过了《关于< 公司 2024 年第一季度报告>的议案》。 ...

证券代码：300253 证券简称：卫宁健康 公告编号：2024-037 本议案在提交董事会审议前已经公司第六届董事会审计委员会 第三次会议审议并取得了全体同意的审查意见。 《2024 年第一季度报告》详见中国证监会指定的创业板信息披 露网站。 特此公告。 第六届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 卫宁健康科技集团股份有限公司（以下简称"公司"）于 2024 年 4 月 25 日在公司会议室以现场和通讯相结合的表决方式召开了第 六届董事会第三次会议。会议通知于 2024 年 4 月 22 日以专人送达或 电子邮件方式发出。会议应出席董事 7 人，实际出席董事 7 人。本次 董事会的召集和召开符合《中华人民共和国公司法》和《公司章程》 的规定。会议由董事长周炜主持，公司监事及高级管理人员列席了本 次董事会。经全体董事表决，形成决议如下： 会议以 7 票同意、0 票反对、0 票弃权的结果审议通过了《关于< 公司 2024 年第一季度报告>的议案》。 卫宁健康科技集团股份有限公司 卫宁健康科技集团股份有限公司 董 事 会 二〇二四 ...

Financial Performance - The company's revenue for Q1 2024 was CNY 494,492,405.71, representing a 10.09% increase compared to CNY 449,172,857.10 in the same period last year[9] - Net profit attributable to shareholders was CNY 16,620,407.26, a significant turnaround from a loss of CNY 63,534,739.90, marking a 126.16% increase[9] - The net profit after deducting non-recurring gains and losses was CNY 8,687,732.19, improving by 111.74% from a loss of CNY 74,028,076.85 in the previous year[9] - Basic earnings per share increased to CNY 0.0077 from a loss of CNY 0.0296, reflecting a 126.01% improvement[9] - The company achieved operating revenue of 494.49 million yuan, a year-on-year increase of 10.09%[45] - Net profit attributable to shareholders reached 16.62 million yuan, up 126.16% year-on-year[45] - The core business of healthcare information technology generated revenue accounting for 89.87% of total revenue, with a year-on-year growth of 16.81%[45] - The total comprehensive income for the current period is 6,494,450.04, compared to -90,204,109.26 in the previous period[60] Cash Flow and Assets - The company's cash flow from operating activities showed a net outflow of CNY 108,888,969.06, worsening by 18.32% compared to CNY 92,026,081.61 in the same period last year[9] - As of March 31, 2024, the company's cash and cash equivalents amounted to CNY 973.09 million, down from CNY 1.114 billion at the beginning of the period[28] - The total current assets as of March 31, 2024, were CNY 4.746 billion, slightly down from CNY 4.854 billion at the beginning of the period[28] - The total cash and cash equivalents at the end of the period is 904,104,252.84, down from 990,968,902.14 in the previous period[62] Liabilities and Equity - The total liabilities decreased to CNY 2,716,898,318.12 from CNY 2,867,668,499.40, reflecting a reduction of about 5.3%[52] - The total equity attributable to shareholders increased to CNY 5,761,421,811.75 from CNY 5,687,089,041.72, an increase of approximately 1.3%[52] Shareholder Information - The number of shareholders at the end of the reporting period was 77,341, with the largest shareholder holding 8.17% of the shares[17] - The company’s total shares held by the top 10 shareholders accounted for 19.63% of the total share capital[39] - The total number of restricted shares at the end of the period was 298,767,886 shares[44] Operational Efficiency - The company recorded a 37.56% decrease in selling expenses, primarily due to reduced personnel costs during the reporting period[14] - Non-operating income decreased by 99.49%, mainly due to a reduction in income not directly related to regular business activities[14] - The company experienced a significant reduction in credit impairment losses and asset impairment losses, decreasing by over 200% due to increased cash collections[37] Investment and Projects - The company utilized CNY 14.1372 million of the raised funds for the "WiNEX MY project," with a cumulative usage of CNY 151.5781 million, achieving a usage progress of 79.08%[25] - The company confirmed government subsidies totaling CNY 26.1561 million, accounting for approximately 7.31% of the audited net profit attributable to shareholders for 2023[27] Revenue Breakdown - Revenue from software sales and technical services accounted for 72.04% of total revenue, growing by 14.89% year-on-year[45] - Revenue from hardware sales represented 17.83% of total revenue, with a year-on-year increase of 25.24%[45] - Internet healthcare revenue accounted for 10.13% of total revenue, showing a decline of 27.10% year-on-year[45] Share Issuance and Corporate Governance - The company issued 6,614,595 new shares as part of its stock option incentive plan during the reporting period[27] - The company completed the election of the sixth board of directors and supervisory board on March 21, 2024[25]

证券代码：300253 证券简称：卫宁健康 公告编号：2024-036 卫宁健康科技集团股份有限公司 关于参股公司卫宁科技股权转让及增资进展 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 卫宁健康科技集团股份有限公司（以下简称"公司"）参股公司上 海金仕达卫宁软件科技有限公司（以下简称"卫宁科技"）为进一步优 化股权结构，壮大资本实力，大力发展商/医保智能风控和数据等业务， 通过股权转让及增资扩股的方式引入新投资人，其中，公司以人民币 7,500 万元向新投资人转让卫宁科技注册资本合计 252.0162 万元；新 投资人以人民币 22,500.00 万元认缴卫宁科技新增注册资本合计 614.4184 万元；卫宁科技员工持股平台以人民币 1,294.8502 万元认 缴卫宁科技新增注册资本 539.5209 万元。上述交易完成后，卫宁科技 注册资本由 6,553.5015 万元变更为 7,707.4408 万元，公司持有卫宁 科技的股权由 36.82%变更为 28.04%。具体内容详见 2023 年 4 月 25 日 披露于巨潮资讯网的《关于参股公司上海金仕达 ...

Investment Rating - The report maintains an "Outperform" rating for the company [3][41]. Core Insights - The company reported a revenue of 3.163 billion yuan for 2023, a year-on-year increase of 2.28%, while the net profit attributable to shareholders reached 358 million yuan, a significant increase of 229.49% [3][24]. - The gross margin improved to 45.0%, up 1.31 percentage points from the previous year, driven by an increase in the proportion of high-margin medical IT business [7][22]. - The company continues to expand its digital health services, with over 10,000 medical institutions served by its platform by the end of 2023, and a monthly active user count exceeding 24 million [11][35]. Financial Performance - The medical IT business grew by 12.66% year-on-year, while the internet healthcare segment saw a decline of 44.53% due to restructuring efforts [25][34]. - The company’s cost control measures were effective, with a sales expense ratio of 14.53%, down 1.51 percentage points, and a management expense ratio of 6.2%, down 0.67 percentage points [17][25]. - The forecast for 2024-2025 revenue has been adjusted to 3.654 billion and 4.167 billion yuan, respectively, with net profit estimates revised to 477 million and 670 million yuan [41][36]. Business Developments - The company launched the WiNGPT AI model in October 2023, marking a significant step in integrating AI into healthcare [40][35]. - The company is focusing on upgrading its core WiNEX product series to enhance its offerings in smart hospitals and digital health [28][35]. - The company has signed contracts worth 268 million yuan in the reporting period, reflecting a year-on-year growth of 122% in its insurance intelligent risk control and data + AI services [11][41].

Investment Rating - The report maintains a "Recommended" rating for the company [5]. Core Insights - The company's revenue for 2023 reached 3.163 billion, a year-on-year increase of 2.28%, while the net profit attributable to shareholders was 358 million, showing a significant growth of 229.49% [5]. - The healthcare information technology business saw a slight increase in new orders, with revenue growing by 12.66% to 2.849 billion in 2023 [6]. - The gross profit margin improved to 45%, up by 1.31 percentage points from the previous year, attributed to the increasing proportion of high-margin healthcare information technology revenue [7]. - The "1+X" strategy continues to evolve, with the WiNEX product line supporting high-quality development in hospital digital transformation [8]. Financial Performance Summary - In 2023, the company achieved a revenue of 3.163 billion, with a growth rate of 2.28% [11]. - The net profit attributable to shareholders was 358 million, reflecting a growth rate of 229.49% [11]. - The company expects revenues of 3.736 billion, 4.349 billion, and 4.907 billion for 2024, 2025, and 2026, respectively, with growth rates of 18.1%, 16.4%, and 12.8% [8]. - The projected net profit for the same years is 563 million, 716 million, and 857 million, with growth rates of 57.4%, 27.2%, and 19.6% [8].

| --- | --- | --- | --- | --- | --- | --- | --- | |----------------------------|----------------------------------------------------------------------------------------------------------------------------------|----------------------------------|------------------------------------------------|----------------|----------------|-----------------------------------------------------------------------|-----------------------| | [Table_Title] | 卫宁健康（ | 300253.SZ | ） | | [ | 公司评级 Table_Invest] | 证券研究报告 \n买入 | | | ...

证券研究报告 2024 年 04 月 20 日 卫宁健康(300253) 盈利恢复，有望受益新一代 WiNEX 和 WiNGPT 推广 事件： 卫宁健康发布 2023 年年度报告，2023 年公司实现营收 31.63 亿元，同比 增长 2.28%；归母净利润 3.58 亿元，同比增长 229.49%；扣非归母净利润 3.33 亿元，同比增长 178.51%；毛利率为 45.00%，同比提升 1.31pct。单 季度来看，第四季度公司实现营收 12.62 亿元，同比增长 3.32%；归母净利 润 2.06 亿元，同比由亏转盈；扣非归母净利润 2.43 亿元，同比由亏转盈； 毛利率为 49.29%，同比提升 7.31pct。 ➢ 医卫信息化软件销售及技术服务营收占比提升 2023 年，公司医疗卫生信息化业务收入同比增长 12.66%，营收占比为 90.05%，同比提升 8.30pct，其中：核心产品软件销售及技术服务业务收入 同比增长 14.59%，营收占比为 74.95%，同比提升 8.05pct；硬件销售业务 收入同比增长 4.00%，营收占比为 15.10%，同比提升 0.25pct。互联网医疗 健康业务收 ...

证券代码：300253 证券简称：卫宁健康 公告编号：2024-035 卫宁健康科技集团股份有限公司 关于取得发明专利证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 卫宁健康科技集团股份有限公司（以下简称"公司"）近日取得 由国家知识产权局颁发的一项发明专利证书。具体情况如下： | 专利名称 | 专利号 | 专利 申请 | 专利 | | 摘要 | | --- | --- | --- | --- | --- | --- | | | | 日 | 权人 | | | | | | | | | 本申请提供一种医疗信息整合方法、装置、计 | | | | | | | 算机设备、介质及系统，涉及医疗信息管理技 | | | | | | | 术领域。该医疗信息整合方法包括：第一机构 | | | | | | | 设备根据患者唯一属性信息，计算第一属性值； | | | | | 卫 | 宁 | 第一机构设备将第一属性值通过区块链设备发 | | 医 疗 信 息 | | 2021 | 健 | 康 | 送至第二机构设备，使得第二机构设备从区块 | | 整合方法、 | | | 科 | ...

Market Presence and Client Base - The company serves over 6,000 healthcare institutions, including more than 400 tertiary hospitals, covering 32 provinces and regions in China[34] - The new WiNEX product has expanded to hundreds of clients nationwide, establishing benchmark clients in various regions[35] - The company aims to enhance market share by leveraging successful implementations of the WiNEX product across various hospitals nationwide, focusing on the demand for smart hospital solutions[175] - The company is actively expanding its brand influence in response to public hospital reforms and the high-quality development of regional medical resources[175] Financial Performance - The company reported a total revenue of approximately CNY 4.2 billion for 2023, with a quarterly breakdown showing Q4 revenue at CNY 1.26 billion, marking a significant increase compared to previous quarters[57] - The net profit attributable to shareholders for Q3 2023 was CNY 205.62 million, while the net loss for Q4 was CNY 31.39 million, indicating fluctuations in profitability throughout the year[57] - Revenue from the healthcare information industry reached ¥2,848,601,352.19, with a year-on-year increase of 12.66%[60] - The company's operating revenue for 2023 reached ¥3,163,424,802.81, representing a 2.28% increase compared to ¥3,092,864,688.21 in 2022[190] - Net profit attributable to shareholders for 2023 was ¥357,959,124.85, a significant increase of 229.49% from ¥108,436,489.10 in 2022[190] Research and Development - R&D investment for the year reached CNY 697 million, accounting for 22.04% of total revenue, reflecting the company's commitment to innovation[55] - The company launched the WiNGPT medical vertical model and integrated it into over 100 clinical application scenarios, enhancing operational efficiency and quality of care[55] - The company is currently developing a new generation of health management software aimed at enhancing market competitiveness and expanding its product line[67] - The company is committed to increasing R&D investment and tracking industry trends to maintain competitive advantages[155] Strategic Initiatives - The company plans to enhance market efforts and improve communication with clients to reduce project implementation time and collection delays[7] - The company is pursuing strategic mergers and acquisitions, including the acquisition of 100% equity in Global Medical by its subsidiary, enhancing its market presence[53] - The company has implemented a "Quality and Return Dual Improvement" action plan to ensure sustainable development and long-term investment value[134] - The company is focusing on expanding its marketing service network to enhance service capabilities[152] Technology and Innovation - The company focuses on the "Internet + healthcare" sector to drive growth and innovation[36] - The company has implemented measures to enhance data security and personal information protection in line with new regulations on generative AI[27] - The company is committed to accelerating the R&D of the WiNEX series products, emphasizing innovation in specialized applications and intelligent adaptations[175] - The company has initiated a digital upgrade of its products and technologies to adapt to market competition in the healthcare industry[102] Cash Flow and Investments - The net cash flow from operating activities was ¥184,799,838.70, showing an 83.99% increase year-on-year[70] - The company reported a gain from the disposal of non-current assets amounting to CNY 57.53 million in 2023, a significant recovery from a loss of CNY 19.54 million in 2022[41] - The total amount of funds raised through the issuance of convertible bonds was 970.265 million, with a net amount of 961.210 million after deducting issuance costs[115] - The company has allocated ¥1,700.86 million of surplus fundraising to supplement working capital for daily operations and business development[101] Risks and Challenges - The company faces risks from intensified industry competition and management challenges due to scale expansion[141] - The company acknowledges various risks, including technology and product development risks, talent loss risks, industry competition risks, management risks, and seasonal performance fluctuations[164] - The company faces potential risks related to goodwill impairment if acquired assets do not meet future operational and profitability expectations, which could adversely affect current earnings[161] Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[190] - The company has outlined its future development outlook and strategic plans, emphasizing the need for investor awareness of the differences between plans, forecasts, and commitments[164] - The company aims to leverage medical data value to drive industry transformation and development[197]